A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F; VISIONARY Study Group

2022
Current Medical Research and Opinion

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Tutkimusz Ltd., Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Ophthalmology, Instituto Oftalmologico Gomez-Ulla, Santiago de Compostela, Galicia, Spain; Department of Ophthalmology, LLC Vzglyad, Leningradskaya, Chita, Russia; Medical Affairs, Santen SA, Geneva, Switzerland; Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications